Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

January Catalysts

- Biotech Showcase (January 12th, 2PM PST)
- Start of cohort 10 (possible dosage increase)
- Start of B-OM (Phase 2)
- Start of K + cytarabine (Phase 1b/2)
- Start of P (Phase 2/3)
- Release of B-ABSSSI bottom line data

Q1 Catalysts

- Start of B-ABSSSI (Phase 3)
- Completion of K (Phase 1)
- Formulations of B-Ocular, B-Otic, diabetic foot infections
- Uplist to NASDAQ

Milestones

- QIDP designation for B-ABSSSI
- B-ABSSSI Phase 2b positive top-line data in ITT and mITT populations
- Completion of cohort 9 (350 mg/m2)
- P Phase 1 primary endpoint met
- Stable formulation of B at room temperature
- Signed agreement for testing B in implanted devices (after FDA approval)

Stock Performances

- 1M: +$1.21 (+38.05%)
- 3M: +$1.43 (+48.31%)
- 6M: +$2.75 (+168.01%)
- 1Y: +$2.36 (+116.47%)

Abbreviations

K – Kevetrin
B – Brilacidin
P – Prurisol
OM – oral mucositis
ABSSSI – acute bacterial skin and skin structure infections
QIDP - qualified infectious disease product

Happy new year to everyone on this board!